ESC 2026 Preview: ACACIA-HCM Hot Line Watch
ESC 2026 lands in Munich from 28 to 31 August 2026 as the year’s main European cardiology catalyst window. For BD and medical affairs, the near-term watch is not logistics alone: Cytokinetics has already locked a Hot Line slot for ACACIA-HCM primary results and two HCM late-breakers, so myosin-inhibitor strategy meetings should be calendared before doors open.
Contents10 sections
Key Takeaways
- ESC Congress 2026 runs 28–31 August 2026 in Munich with a full scientific programme and online components.
- Cytokinetics scheduled an ACACIA-HCM Hot Line on Friday 28 August 2026 at 11:45–11:55 CEST in the Main Auditorium.
- Two additional aficamten late-breaking HCM abstracts are set for Saturday 29 August 2026 (imaging/structure and MAPLE-HCM subgroup work).
- ACACIA-HCM is registered as NCT06081894; full efficacy numbers at the podium are not yet public and must not be assumed.
ESC 2026 at a glance
| Field | Detail |
|---|---|
| Congress | ESC 2026 (ESC Congress) |
| Dates | 28–31 August 2026 |
| City | Munich, Germany |
| Format | Onsite + online / on-demand windows per ESC registration pages |
| Regional hub | Europe Events |
| Near-term BD anchor | ACACIA-HCM Hot Line (aficamten in nHCM) |
What is on the ESC 2026 agenda for BD?
The official ESC Congress site lists ESC Congress 2026 for 28–31 August in Munich and points teams to the scientific programme planner for session-level booking. Late onsite registration savings are flagged through 31 July 2026 on ESC deadline copy, so travel and booth plans should already be locked.
For commercial diligence, treat Hot Line and Late-Breaking Clinical Science rooms as the scarce inventory. Those sessions concentrate first disclosures that can reset label expansion talks, payer dossiers, and competitive messaging in hypertrophic cardiomyopathy and adjacent heart-failure franchises.
Which companies have catalyst risk at ESC 2026?
Cytokinetics is the clearest named catalyst so far. In a 7 July 2026 GlobeNewswire release, the company said three Late Breaking Science abstracts were accepted for ESC Congress 2026 in Munich, including a Hot Line of primary results from ACACIA-HCM in symptomatic non-obstructive HCM.
Session logistics from that release: Hot Line 1 on Friday 28 August 2026, 11:00–12:15 CEST, with the ACACIA-HCM talk at 11:45–11:55 CEST (presenter Ahmad Masri, M.D., M.S.). Saturday 29 August adds Late-Breaking Clinical Science: Hypertrophic Cardiomyopathy at 16:15–17:15 CEST, covering ACACIA echocardiographic remodeling and a MAPLE-HCM aficamten-versus-metoprolol analysis.
Earlier in 2026, Cytokinetics also used the separate ESC Heart Failure congress to deepen the oHCM evidence base for MYQORZO (aficamten). That path matters for BD because oHCM approval is already in place in the U.S., EU, and China per company disclosures, while nHCM remains an expansion bet tied to ACACIA-HCM.
What does ACACIA-HCM test?
ClinicalTrials.gov NCT06081894 describes ACACIA-HCM as a Phase 3, randomized, double-blind, placebo-controlled study of aficamten in adults with symptomatic non-obstructive HCM. The registry lists dual primary endpoints at Week 36: change in KCCQ-CSS and change in peak VO2, with estimated enrollment of about 500 participants.
Until Hot Line slides post, BD models should keep effect-size and safety cells blank. The registry design tells you what will be measured; it does not authorize invented ORR-style cardiology endpoints or stock-move narratives.
How should partnering teams use the four days in Munich?
Build a watchlist around three buckets: (1) confirmed late-breakers with wire confirmation, (2) ESC guideline and association tracks that change standard-of-care language, and (3) industry theatres where dose, device, or digital-endpoint stories surface without a Hot Line stamp.
- Pre-book Hot Line 1 on 28 August and the HCM late-breaker block on 29 August.
- Map competitor myosin-inhibitor and heart-failure asset owners to the same rooms.
- Capture primary slides the same day; do not rely on secondary recaps for diligence memos.
- Hold label-expansion and BD term sheets until primary endpoints and safety are on the record.
NHLBI’s public overview of hypertrophic cardiomyopathy remains useful background for non-specialist stakeholders preparing for the meeting: NHLBI hypertrophic cardiomyopathy page.
What remains unproven before ESC 2026?
Company acceptance of a Hot Line does not prove ACACIA-HCM met its dual primaries, nor that regulators will accept any particular filing package. MAPLE-HCM and imaging late-breakers are subgroup or mechanism stories unless the presenters state otherwise. Avoid pricing or peak-sales updates until the Munich data are public.
Related NovaPharma coverage
- Cytokinetics MYQORZO (aficamten) at ESC Heart Failure 2026
- ISPOR 2026 cardiology highlights
- ESC 2026 event hub
- Europe Events listing
Frequently Asked Questions
When and where is ESC 2026?
ESC Congress 2026 runs 28–31 August 2026 in Munich, Germany, with onsite and online access per the ESC programme pages.
What should BD teams watch at ESC 2026?
Priority is Cytokinetics’ ACACIA-HCM Hot Line on 28 August 2026 and two aficamten late-breaking HCM science sessions on 29 August, plus guideline and HF tracks.
Which trial underpins the ESC 2026 Hot Line?
ACACIA-HCM (NCT06081894) is the Phase 3 placebo-controlled study of aficamten in symptomatic non-obstructive HCM listed on ClinicalTrials.gov.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
